New combo therapy shows promise for tough cancers
NCT ID NCT04879849
First seen Nov 01, 2025 · Last updated May 19, 2026 · Updated 27 times
Summary
This early-phase study tested a new drug (TAK-676) combined with pembrolizumab after radiation in 34 adults with lung, triple-negative breast, or head/neck cancers that had stopped responding to standard treatments. The main goals were to check safety, side effects, and find the best dose. Participants received radiation first, then the drug combo every 3 weeks. Results help guide future research on controlling these hard-to-treat cancers.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Cedars Sinai Medical Center
Duarte, California, 91010-3012, United States
-
Laura And Isaac Perlmutter Cancer Center
New York, New York, 10016-4744, United States
-
Providence Portland Medical Center
Portland, Oregon, 97213-2933, United States
-
University of Chicago
Chicago, Illinois, 60637-1443, United States
-
Vanderbilt University Medical Center
Nashville, Tennessee, 37232-0021, United States
Conditions
Explore the condition pages connected to this study.